Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
107.57
(
-0.52%
)
Bitcoin
67,667.45
(
-0.25%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biopearl post# 3240

Tuesday, 04/10/2007 2:10:31 PM

Tuesday, April 10, 2007 2:10:31 PM

Post# of 19309
Notes on today’s IP news:

1. The news is neutral for GTC.

2. GTC had originally licensed this nuclear-transfer patent from ACTC, but ACTC lost a patent case vs GERN and thereby lost ownership of the IP (#msg- 13128835).

3. Now, GTC has licensed the same patent from Start Licensing Inc. (i.e. GERN) for what is presumably a similar (small) royalty to what GTC would have paid ACTC.

4. The new license has no effect whatsoever on ATryn, which is produced using micro-injection rather than nuclear transfer.

Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today